Northwest Biotherapeutics (NWBO) Income from Continuing Operations (2010 - 2026)

Northwest Biotherapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 13246000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 29.96% year-over-year to 13246000.0 in Q1 2026; TTM through Mar 2026 was 71063000.0, a 12.47% increase from a year earlier, with the FY2025 full-year figure at 60699000.0, up 27.55% from the prior year.
• Income from Continuing Operations grew to 13246000.0 in Q1 2026 per NWBO's latest filing, from 16126000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 11988000.0 in Q4 2023 and bottomed at 130235000.0 in Q3 2022.
• The 5-year median for Income from Continuing Operations is 16941000.0 (2025), against an average of 24252823.53.
• Across the five-year window, Income from Continuing Operations sank 1017.61% in 2022 and surged 88.08% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 19446000.0 in 2022, then surged by 38.35% to 11988000.0 in 2023, then sank by 118.81% to 26231000.0 in 2024, then surged by 38.52% to 16126000.0 in 2025, then increased by 17.86% to 13246000.0 in 2026.
• Per Business Quant, the three latest NWBO Income from Continuing Operations figures stand at 13246000.0 (Q1 2026), 16126000.0 (Q4 2025), and 16941000.0 (Q3 2025).